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he summer of 2006 was a heady time for neurologist 
Douglas Kerr. As Director of the Johns Hopkins 
Transverse Myelitis Center in Maryland, Kerr studies 
the mechanisms of neurodegenerative diseases in the hope 
of developing therapies to treat them. He sees patients with 
transverse myelitis, amyotrophic lateral sclerosis, and spinal 
muscular atrophy (SMA), an inherited disorder that in 
its most severe form renders newborns limp and “ﬂ  oppy,” 
unable to suck, swallow, or breathe. Kerr’s voice tightens as 
he describes the fate of these babies, many of whom will die 
before their second birthday. He’s convinced that embryonic 
stem cells will one day help people with progressive, motor-
neuron-destroying disorders recover control of their 
movements, and their lives. 
For six long years, Kerr’s team pursued the elusive elixir 
that would restore mobility to the paralyzed adult rats he uses 
to model neurodegeneration in humans. The researchers had 
cleared two major technical hurdles early on: they managed 
to derive spinal motor neurons from mouse embryonic stem 
cells in sufﬁ  cient numbers to transplant in the rats’ spinal 
cords, and they ensured the transplanted neurons’ survival. 
But they struggled for years to prod the spinal motor neurons 
to send their axons out of the spinal cord and form functional 
neuromuscular junctions with the lame muscle.
Finally, in 2005, they hit the mark. Growth factors injected 
into the spinal cord induced the transplanted motor neurons 
to form connections with resident neurons. A second set of 
growth factors overcame inhibitors in myelin (the protective 
sheath around nerves that blocks axon growth in adult 
animals), allowing the motor neurons to send their axons out 
of the spinal cord toward skeletal muscle. And yet another 
growth factor injected into the muscle stimulated functional 
connections between the neurons and muscle. Kerr watched 
his rats—immobilized with a motor-neuron-destroying 
virus—move hind limbs that had been paralyzed for nearly 
four months. (Watch before and after videos of the rats on 
the Johns Hopkins Web site, http:⁄⁄www.hopkinsmedicine.
org/Press_releases/2006/Mousevideo.html.) 
When Kerr and his colleagues reported their results in 
the June 2006 online version of Annals of Neurology, the work 
was widely hailed as the ﬁ  rst evidence that stem-cell-based 
therapy could recapitulate early developmental signals and 
rewire a damaged neural circuit. Elias Zerhouni, Director 
of the US National Institutes of Health (NIH), which 
funded part of the research, called the work a “remarkable 
advance” demonstrating the power of stem cells to treat 
neurodegenerative diseases. All those years of frustration had 
ﬁ  nally paid off. But would the technique work in humans?
To ﬁ  nd out, Kerr must use motor neurons derived from 
human embryonic stem cells (hESCs) and show that they can 
establish functional connections with skeletal muscle over the 
longer distances found in a larger animal. (He’s settled on 
pigs.) He must also show that the treatments are safe. If the 
pig experiments generate the necessary safety and efﬁ  cacy 
data, he will submit his results to the US Food and Drug 
Administration, seeking approval for a clinical trial to use the 
hESC-derived motor neurons in babies with fatal SMA. 
Kerr chose babies with SMA for the ﬁ  rst clinical trials, he 
explains, because infants have less myelin to inhibit axon 
growth, so the chance of re-innervation is greater. Their 
neurons need travel just a short distance compared to adults, 
and the developmental cues that guide axon growth toward 
their appropriate targets are still in place. And because no 
treatment or cure exists for these babies, an experimental 
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treatment represents their only hope. Kerr had planned to 
use federally approved hESCs until he found out that the 
federal lines could not reliably yield motor neurons with 
anywhere near the efﬁ  ciency of newer lines generated with 
private funds. (In the rat experiments, each animal had 
60,000 motor neurons transplanted into their spinal cord.) 
Still, Kerr watched hopefully as a bipartisan bill authorizing 
expanded federal ﬁ  nancing of hESC research passed the US 
House of Representatives in 2005 and then the Senate last 
year. In addition to allowing federally funded researchers to 
derive new hESC lines from embryos awaiting destruction 
in fertility clinics, the Stem Cell Research Enhancement Act 
would lift the ban on lines derived after August 2001. But 
President George W. Bush vetoed the bill in July 2006, and 
“put a real chill on things,” Kerr says. Now Kerr is worried 
that if he acquires the pigs and prepares them for the 
stem cell therapy, he’ll run into a brick wall when the time 
comes to get the hESCs he needs for the transplantation 
experiments. 
Even though Maryland passed a measure in 2006 to spend 
$15 million on hESC research, Kerr says that’s just a one-time 
appropriation. Working with live animals costs several million 
dollars. “What am I going to do next year when I’ve got all 
those animals?” he asks. 
Kerr won’t qualify for federal funding if he uses non-
approved lines, but he’s not willing to risk the potential 
problems with the federally sanctioned lines. And adult 
stem cells aren’t an option. He tried to generate spinal 
motor neurons from adult stem cells and cells isolated from 
umbilical cord blood, but decided that programming a blank 
slate—hESCs—is far more efﬁ  cient than deprogramming 
specialized cells and redirecting them toward a different 
fate. He put everything on hold, pending the outcome of the 
November midterm elections. 
A Political Straitjacket
The use of federal funds to create or destroy human embryos 
for research was outlawed in the US by Congress in 1997. On 
August 9, 2001, when President Bush announced his decision 
to allow federal funding to support hESC research only on 
lines already derived—because “the life and death decision 
has already been made”—scientists were just learning what 
the cells needed to thrive and maintain their “stemness,” 
the ability to self-renew and differentiate into any cell type 
of the body (called pluripotency). Methods used to derive 
these early hESC lines were technically demanding and 
labor-intensive, requiring the artful touch of a highly skilled 
technician to tease apart cells with a glass needle to propagate 
the cell lines (a technique called mechanical passaging). 
The lines were also grown on mouse ﬁ  broblasts—cells 
that act as “feeder” layers to maintain the stem cells in an 
undifferentiated state—increasing the risk that the human 
cells would absorb mouse molecules and trigger rejection by 
the immune system if used in clinical trials.
Scientists have since ﬁ  gured out how to wean the human 
cells off the mouse feeder cells, but the process is time-
consuming. A team of researchers working in Miodrag 
Stojkovic’s lab at the University of Newcastle, UK, developed 
a method of deriving hESCs that eliminates the risk of 
contamination from both mice and human donors. In 
their “autogenic” feeder system, a parental hESC line gives 
rise to a subset of differentiated ﬁ  broblasts that sustain 
the parental line. While Stojkovic’s lines were grown on 
medium containing animal products, he says that this 
approach demonstrates how researchers can generate 
clinical-grade hESC lines that would meet the Federal Drug 
Administration’s Good Manufacturing Practices safety 
requirements. Last July, the Singapore biotech company 
ESI announced that it had derived four safe lines of hESCs 
for clinical use. And the Hadassah Medical Organization in 
Israel recently developed animal-free methods for isolating 
pluripotent stem cells from human embryos (obtained from 
in vitro fertilization clinics) and deriving new clinical-grade 
hESC lines. These are just the types of cells Kerr could use 
for his pig experiments—if he were free to use any lines he 
wanted.
Carol Ware, Director of the Human Embryonic Stem Cell 
Core Laboratory at the University of Washington School of 
Medicine, has been working to characterize the available 
NIH-approved hESC lines. So far, Ware and her colleagues 
have tested 14 of the 22 available lines (a 15th line arrived at 
the lab contaminated with mycoplasma) for growth efﬁ  ciency, 
genomic stability, appropriate gene expression during self-
renewal and differentiation, and other NIH criteria. 
The team found considerable variation among the lines. 
Some lines had a propensity to develop chromosomal 
abnormalities over time, and others were hard to grow. 
“Certain lines are very difﬁ  cult to thaw,” Ware says, “so you 
may only get one or two cells.” Not a great return for cell lines 
that cost between $2,500 and $6,000. 
Complicating matters further, the cells seem to prefer the 
culture conditions in which they were derived. All of the 
lines were originally derived through mechanical passage. 
And though some were eventually converted to enzymatic 
passage—a speedy, less onerous technique that has become 
the standard method for expanding hESC lines—it’s not 
possible to predict which lines can convert to enzymatic 
passage, further compromising their utility. 
Mechanically passaging lines is “a real pain in the neck,” 
says Larry Goldstein, Director of the University of San Diego 
Stem Cell Program, likening the technique to early versions of 
a software program that still need debugging. Goldstein’s lab 
has been exploring the properties of some of the federal lines, 
and still uses one of the approved lines in experiments. “It’s 
been okay in some areas, and a little tougher in others,” he 
says. “Others use it and are happy with it.” 
The lines “certainly aren’t useless,” he adds, but he’s found 
them clumsy to handle. “For our experiments, we need cell 
lines that grow well for more than just the most-skilled tissue 
person. If only one person in the lab is sufﬁ  ciently skilled to 
grow them, you’re not going to get much done.” Goldstein 
plans to investigate non-approved lines with private or state 
funding.
Kerr had planned to use federally 
approved hESCs until he found out 
that the federal lines could not reliably 
yield motor neurons with anywhere 
near the efﬁ  ciency of newer lines 
generated with private funds.
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Ware found that lines also varied in their ability to form 
different tissues, suggesting that each line may possess unique 
capabilities. This variable behavior may arise from differences 
in the way the lines were derived or in the inherent properties 
of the cells themselves, the team reported online on August 17, 
2006, in Stem Cells. Either way, they concluded, it underscores 
the need to derive and study additional hESC lines. 
Harvard researcher Doug Melton came to the same 
conclusion even before the Bush administration restrictions 
were put in place, when he began looking for hESCs for his 
work on type I diabetes in the late 1990s. Disappointed with 
what he found, he decided to generate his own lines, and in 
2004, Melton and his team announced that they had derived 
17 new hESC lines, using funding from the Howard Hughes 
Medical Institute and the Juvenile Diabetes Research 
Foundation. Melton’s team used enzymatic passaging to 
make the lines more user-friendly, allowing far more labs to 
handle the cells, provided they ﬁ  nd state or private funding. 
The Harvard lines, as they’re known, are also available free 
of charge. 
Ware believes the federal lines will become historical lines, 
as technological advances have already made the older lines 
seem outdated. “We’re understanding culture techniques 
so much better now, and as you understand more and more 
what the cells want, you’re going to get better lines.”
States and Private Donors Step In
US advocates of stem cell research read the 2006 midterm 
election results as a sign that embryonic stem cell research 
has gained widespread bipartisan support. They point to 
Missouri as the bellwether state. For the past ﬁ  ve years, 
Missouri lawmakers tried to pass a measure to criminalize stem 
cell research in the state. But last November, voters not only 
approved a state constitutional amendment protecting stem 
cell research, but ousted incumbent US Senator Jim Talent, 
who called stem cell research “morally reprehensible,” in favor 
of Claire McCaskill, a vocal supporter of hESC research. Stem 
cell research ﬁ  gured prominently in six US Senate races; in 
each case, the candidate who supported stem cells won. 
“The political dynamic in the 110th Congress is going to 
be a lot different than it was in the 109th,” says Sean Tipton, 
President of the Coalition for the Advancement of Medical 
Research, a stem cell advocacy group. Tipton thinks the new 
Congress will be even more supportive than the 109th, which 
passed the Stem Cell Research Enhancement Act with strong 
bipartisan support. 
Douglas Kerr goes even further. He’s conﬁ  dent the bill will 
pass this year with a veto-proof majority, and that “we’ll have 
federal funding in 2007.”
But what the next year holds is unclear. Nancy Pelosi, who 
will preside over the House of Representatives as Speaker 
when the new Congress convenes in January, has pledged to 
“promote stem cell research to offer real hope to the millions 
of American families who suffer from devastating diseases” 
in Congress’s ﬁ  rst 100 hours. But an analysis based on the 
stated stem cell positions of the newly constituted House and 
Senate by The Chronicle of Higher Education found that if the 
stem cell act were reintroduced, votes in the House would fall 
short of a veto-proof majority. And few doubt that Bush would 
exercise his veto prerogative. 
While the federal prospects remain uncertain, states 
are increasingly ﬁ  lling the void. A 2006 Congressional 
Research Service report to Congress lists 12 states as actively 
encouraging or funding stem cell research, with Wisconsin 
and California leading the way. The California Institute of 
Regenerative Medicine (CIRM), created to oversee the $3 
billion stem cell research program authorized by voters in 
2004, awarded $12 million in training grants last April and 
expects to award over 55 research grants totaling over $100 
million in early 2007. Grant allocations were initially stalled by 
lawsuits ﬁ  led by pro-life and anti-tax groups, until Governor 
Arnold Schwarzenegger stepped in with a $150 million 
state loan, and private donors and foundations pledged $45 
million in loans against the bond to get the ball rolling. 
All this support from states and private donors puts more 
scientists to work, says Dale Carlson, Chief Communications 
Ofﬁ  cer for CIRM. With the uncertainty at the federal level, 
he says, it’s important that the states and private donors are 
stepping in, “instead of scientists stepping back and waiting 
till the policy changes.”
While senior scientists acknowledge the difﬁ  culty of 
recruiting the best young minds to a ﬁ  eld so mired in 
controversy, those hot on the trail of potential cures using 
stem cells are not about to sit idly by while Washington 
ﬁ  ddles. Kerr is hoping for the best in 2007, but he and 
his California collaborator, Hans Keirstead, are pursuing 
nonfederal funding “while we await changes in D. C.” Both 
are appealing to private philanthropy groups for bridge 
funding to make sure their work continues. 
In November, CIRM received 70 applications for 
comprehensive research grants totaling $80 million. 
University of California San Diego’s Goldstein was among 
the applicants, voicing frustration with the limitations on 
scientiﬁ  c freedom imposed by the federal restrictions. “Bush’s 
policy hasn’t spared any frozen embryos as far as I know,” he 
says. “The biggest destruction of human blastocysts happens 
in IVF clinics and that hasn’t changed.”
Meanwhile the research moves ahead without the 
centralized control and oversight of the federal government. 
The lack of federal support means that US researchers—who 
led the way in setting standards for genetic testing and 
genome sequencing—cannot do the same for embryonic 
stem cell research. Although CIRM and the National 
Academy of Sciences are setting research guidelines for state-
funded researchers, if US researchers aren’t at the forefront 
of the ﬁ  eld, they can’t lead by example. 
But scarce research dollars, some researchers believe, is 
an even bigger problem. In an era of shrinking NIH budgets 
and heightened competition for federal grants, restricting 
grantees to the less tractable NIH-approved lines means the 
Ware and her colleagues have 
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NIH lines for growth efﬁ  ciency, 
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federal government is spending less money on stem cell 
research, and spending it less efﬁ  ciently. “As a scientist you 
want to have the maximum number of tools available because 
the research problems are hard enough, even when the lines 
behave well,” Goldstein says. “And these aren’t just theoretical 
problems. We’re trying to ﬁ  gure out what’s gone wrong with 
these terrible diseases that afﬂ  ict large numbers of people.” 
The federal restrictions, he says, have forced the community 
to work with one hand tied behind its back.
That means that if a US researcher who has access to ten 
or 15 federally approved hESC lines is working on the same 
question as a researcher in Singapore, for example, who 
may have access to 100 lines, the US researcher can’t hope 
to compete. With reports that some lines appear genetically 
predisposed to behave one way or another, therapeutic 
applications may require creating stem cell lines that are 
genetically identical to the patient, to prevent immune 
rejection. That’s a question that researchers like Douglas Kerr 
can’t ask if they’re restricted to the limited diversity of ten 
hard-to-grow stem cell lines.
With the right cells in hand, Kerr would ﬁ  rst seek proof of 
principle that his neuroregenerative stem cell therapy can 
work in pigs, and then move on to see if it can help babies 
with SMA—a path he’s charting in a grant right now. If the 
results showed that the researchers were on the right track, 
they would move on to test this type of therapy in patients 
with the more complex lesions found in transverse myelitis, 
amyotrophic lateral sclerosis, and traumatic spinal cord 
injury. Aside from a political sea change that lifts the federal 
restriction on stem cell research—a shift that may have 
arrived with the 110th Congress, or may still come up a few 
votes short—what does Kerr’s group need to move forward? 
“If we got ten good lines that were genetically normal, and 
had not come into contact with other species, and could 
become motor neurons,” he says, “we’d be set.”  
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